Immunome, Inc. (IMNM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.76-1.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Immunome is developing antibody therapies with promising Phase 3 data for varegacestat. The company aims to fund operations through 2028, supporting continued development. Recent positive earnings beats show some operational progress. The stock has gained nearly 24% over 3 months, reflecting improving sentiment.
Immunome remains unprofitable with negative EPS around -$2.1 expected in 2026 and 2027. Recent Phase 3 data showed mixed results, with some negative headlines challenging key trials. The company faces elevated risk and has no clear revenue growth guidance.
The market price is about 6% below our valuation midpoint and roughly 28% below the Street median. This suggests cautious optimism but also reflects uncertainty about the company’s turnaround and profitability timeline.
Breaks if: Company fails to maintain cash to fund operations through 2028
Immunome aims to maintain its cash position to fund operations through 2028.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown weak recent performance, but the stable management and favorable sector conditions provide a mixed outlook.
The market appears to have low expectations for IMNM, as indicated by its premium valuation compared to peers. There is a low fragility tier, suggesting that the current pricing does not reflect significant risk factors.
Fundamentally, IMNM's performance is at risk due to a high probability of missing earnings expectations. Recent changes indicate a decline in company quality, which could impact future results.
The long-term thesis hinges on management's ability to navigate operational challenges and the performance of sector bellwethers. Additionally, any cuts to guidance or worsening economic indicators could negatively affect sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -$2.1 in FY26 or FY27
Breaks if: Negative Phase 3 RINGSIDE data undermines trial objectives
Over the next 1 to 3 years, IMNM's outlook is mixed, with potential upside if sector momentum continues but significant risks if guidance is cut or economic conditions worsen. Not investment advice.